Fresenius poised to issue more debt for NxStage buy

Fresenius, from corp website
By Max Bower
08 Aug 2017

German dialysis services provider Fresenius will issue debt backing its $2bn acquisition of US peer NxStage “in due course”, a source close to the situation told GlobalCapital on Tuesday.

Fresenius Medical Care North America agreed on Monday to buy all outstanding shares in Massachusetts-based medical technology firm NxStage at $30 a share.

That represents a 29% premium to NxStage’s closing share price of $23.14 on Friday and represents an enterprise value of $2bn, about five times its ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.